TLRY Tilray

Good Supply Cannabis Brand Launches ‘Peppermint Phatty’

Good Supply Cannabis Brand Launches ‘Peppermint Phatty’

New 510 Thread Vape Cartridge Now Available Across Canada

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today the launch of Peppermint Phatty 510 vape, the newest addition to the Good Supply vape lineup.

Just in time for the holidays, Peppermint Phatty is packed with peppermint and vanilla aromas and topped off with a slight cooling sensation. These 1g 510 cartridges deliver our most potent vape yet and provide a refreshing touch with every minty pull.

“With the launch of Peppermint Phatty, our most refreshing tasting vape yet, customers can expect the same features like high quality cartridges and innovative flavour formulations that have made Good Supply so recognizable and respected among Canadian cannabis enthusiasts,” said Michelle Morin, Brand Manager.

Good Supply’s Peppermint Phatty vape is now available across Canada.

About Good Supply

Good Supply is one of Canada's leading cannabis brands in flower, pre-rolls, vapes, concentrates, and has become a favourite among consumers and budtenders. At Good Supply good is the new great. Rooted in classic strains that punch above their weight, Good Supply has been one of the top-selling brands in the concentrates and pre-roll category within Canada and is known for its innovative take on its products across its expansive portfolio.

To learn more about Good Supply, visit  and follow @goodsupplycannabis.

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray, visit  and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

__________

Forward-Looking Statements



Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

Contacts:

Tilray Global:

Kaitlin Macapagal

Investors

Raphael Gross

203-682-8253



EN
06/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tilray

 PRESS RELEASE

Tilray Medical veröffentlicht bahnbrechende Forschungsergebnisse zur P...

Tilray Medical veröffentlicht bahnbrechende Forschungsergebnisse zur Pharmakokinetik von THC- und CBD-Formulierungen Neue Studie liefert Erkenntnisse über die Bioverfügbarkeit von medizinischen Cannabisformulierungen für therapeutische Behandlungen NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ein Geschäftsbereich von Tilray Brands, Inc. („Tilray” oder das „Unternehmen”) (Nasdaq: TLRY; TSX: TLRY) und ein weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische Allianz zwischen Patienten und Ärzten stärkt, um fundierte, individuelle Gesundheitsentschei...

 PRESS RELEASE

Tilray Medical publie une recherche pionnière sur la pharmacocinétique...

Tilray Medical publie une recherche pionnière sur la pharmacocinétique des formulations de THC et de CBD La nouvelle étude fournit des informations sur la biodisponibilité des formulations de cannabis thérapeutique à des fins thérapeutiques NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc. (« Tilray » ou la « Société ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui favorise l’alliance thérapeutique entre les patients et les professionnels de santé afin de leur permettre de prendre des décisions éclairées et per...

 PRESS RELEASE

Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaborat...

Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider Foundation Two iconic coastal-living brands team up for a limited-edition summer beer and capsule collection MONTAUK, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- ., the brewery known for capturing the essence of coastal living and a craft beer brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is partnering with premium lifestyle brand to craft a limited-edition beer and beachside inspired apparel collection that embodies the carefree spirit of Montauk and effortl...

 PRESS RELEASE

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics o...

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic Treatment NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced the publication of a scientific study. This new ...

 PRESS RELEASE

Tilray Medical erhält vom italienischen Gesundheitsministerium die ers...

Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische Zusammenarbeit zwischen Patienten und Ärzten fördert, um fundierte, individuelle Gesundheitsentscheidungen zu ermöglichen, hat heute einen bedeutenden Meilenstein in seiner Expansion in Europa bekann...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch